Literature DB >> 12882718

The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Chris M Gonzalez1, Kevin T McVary.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12882718     DOI： 10.1007/s11934-003-0084-1

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   2.862


× No keyword cloud information.
  23 in total

Review 1.  Medical management of benign prostatic hyperplasia with androgen suppression.

Authors:  J D McConnell
Journal:  Prostate Suppl       Date:  1990

2.  The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy.

Authors:  M Caine
Journal:  J Urol       Date:  1986-07       Impact factor: 7.450

3.  Pathophysiology of clinical benign prostatic hyperplasia.

Authors:  E Shapiro; H Lepor
Journal:  Urol Clin North Am       Date:  1995-05       Impact factor: 2.241

4.  Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia.

Authors:  G Bartsch; H R Müller; M Oberholzer; H P Rohr
Journal:  J Urol       Date:  1979-10       Impact factor: 7.450

5.  Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.

Authors:  F M Debruyne; A Jardin; D Colloi; L Resel; W P Witjes; M C Delauche-Cavallier; C McCarthy; C Geffriaud-Ricouard
Journal:  Eur Urol       Date:  1998-09       Impact factor: 20.096

Review 6.  Are all alpha-blockers created equal? An update.

Authors:  Claus G Roehrborn
Journal:  Urology       Date:  2002-02       Impact factor: 2.649

7.  Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group.

Authors: 
Journal:  Prostate       Date:  1993       Impact factor: 4.104

8.  The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle.

Authors:  E Shapiro; V Hartanto; H Lepor
Journal:  Prostate       Date:  1992       Impact factor: 4.104

9.  Proscar: five-year experience.

Authors:  E Moore; B Bracken; W Bremner; J Geller; J Imperato-McGinley; J McConnell; J Roy; L Tenover; D Vaughan; F Pappas
Journal:  Eur Urol       Date:  1995       Impact factor: 20.096

10.  The development of human benign prostatic hyperplasia with age.

Authors:  S J Berry; D S Coffey; P C Walsh; L L Ewing
Journal:  J Urol       Date:  1984-09       Impact factor: 7.450
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.